Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19
- Monday, December 27, 2021, 7:40
- PR Newswire
- Add a comment
SUZHOU, China, Dec. 27, 2021 /PRNewswire/ — Kintor Pharmaceutical Limited (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today provided an update on its multi-regional study of proxalutamide for the…
About the Author
admin has written 20652 stories on this site.